Tinengotinib demonstrated a complete mass balance, and excretion was predominantly through feces (92.46% in feces and 7.11% in urine).

Tinengotinib is metabolized via CYP3A4, with the parent drug representing 88.23% of total circulating radioactivity AUC and three minor metabolites (each < 5%).

These findings provide support for the clinical pharmacology development program including drug–drug interaction (DDI) potential and special populations investigations.